Context: Short-term glucocorticoid exposure increases serum insulinlike growth factor I (IGF-I) concentrations but antagonizes IGF-I tissue signaling. The underlying mechanisms remain unknown.
G lucocorticoid excess accelerates protein breakdown and inhibits protein synthesis in many tissues and may ultimately cause muscle atrophy, osteoporosis, and impaired linear growth (1) (2) (3) . The catabolic effects of glucocorticoids are mediated at least partly by suppression of insulinlike growth factor I (IGF-I) signaling. Shortterm and long-term glucocorticoid excess suppresses the ability of serum IGF-I to stimulate protein and DNA synthesis (4-7), whereas stimulation of endogenous IGF-I by growth hormone administration can diminish catabolic effects of long-term glucocorticoid therapy (2) .
Even though short-term glucocorticoid exposure appears to decrease IGF-I action, circulating IGF-I concentrations increase (6, 8, 9) . Consequently, interest has focused on IGF-binding proteins (IGFBPs), which modulate IGF-I action. However, the observed changes in IGFBP concentrations following glucocorticoid administration do not align with a reduced serum IGF-I action, and circulating levels of free IGF-I remain either unchanged or increase by glucocorticoid treatment (6, 7, (9) (10) (11) (12) . On this basis, it has been hypothesized that glucocorticoid treatment induces a yet unidentified circulating inhibitor of IGF-I action (5, 6, 10) . Another hypothesis is that glucocorticoid impedes the intracellular signal transduction of the IGF-I receptor (IGF-IR) through inhibition of insulin receptor substrate 1 (IRS-1) (13) .
The majority of IGF-I is complexed to IGFBPs. This is true for circulating IGF-I (14) and most likely also for tissue IGF-I (15) (16) (17) (18) (19) . As IGFBP-complexed IGF-I is physically inaccessible to the IGF-IR, liberation of bound IGF-I is believed to constitute a mainstay in the regulation of IGF-I action (20) .
Liberation of bound IGF-I is controlled by a number of IGFBP-specific and IGFBP-unspecific proteases (21) . Pregnancy-associated plasma protein A (PAPP-A) and PAPP-A2 are specific proteases, which cleave individual IGFBPs and thereby regulate local IGF-I action (22, 23) . Recently, stanniocalcin 2 (STC2), a widely secreted glycoprotein, was identified as a potent inhibitor of PAPP-A and PAPP-A2 proteolytic activity (24, 25) . Whereas the regulators of PAPP-A2 have yet to be determined, the expression of PAPP-A is stimulated by proinflammatory proteins (26) . Whether glucocorticoids are able to affect the PAPP-As remain unknown.
To investigate how glucocorticoid inhibits IGF-I action, we performed a placebo-controlled randomized clinical trial, comparing the effect of 5 days of prednisolone treatment (37.5 mg/d) vs placebo treatment on serum and interstitial fluid levels of the IGF system, focusing on the STC2-PAPP-A/PAPP-A2-IGFBP axis and their impact on IGF-IR activation.
Materials and Methods

Ethical approval
All participants gave written, informed consent in accordance with the Declaration of Helsinki II. The study was conducted after approval from the Regional Scientific Ethical Committee and Danish Health and Medicine Authority, and it was monitored by the local Good Clinical Practice Unit. The study was reported at www.clinicaltrial.gov (ID number: NCT01762540) and at the European Union clinical trial register EUDRA-CT (ID number: 2012-003504-12).
Participants
The study included 19 euglycemic, healthy men (Table 1) who received no prescribed medication. All participants underwent routine biochemical testing, a medical interview, and a physical examination. Participants were instructed to maintain their usual physical activity level and to comply with recommended sleeping hours prior to the study days.
Study design and protocol
The study was designed as a randomized, double-blinded, placebo-controlled crossover trial. All participants received 5 days of 37.5 mg prednisolone and 5 days of placebo, administered orally once daily in the morning. The prednisolone dose results in supraphysiological glucocorticoid effects, but the dose is clinically relevant and normally well tolerated during short-term treatment.
Each study session was separated by a washout period of a minimum of 4 weeks. Overnight fasting serum and EDTA plasma were collected on day 1 [i.e., before the first dose was given (baseline)] and on days 3 and 5 of each treatment. At day 5, suction blister fluid (SBF) was collected in nine participants (please see below). Skeletal muscle biopsy specimens were obtained from all participants using a Bergström needle after application of local anesthetics. Screening and enrollment of study participants were conducted by the investigators and randomization by the hospital pharmacy. Tablets containing prednisolone or placebo (calcium supplement) were encapsulated to blind participants and investigators. The randomization list was kept at the pharmacy until trial end. To assess compliance, participants were asked to bring empty pill containers on the final day of each session.
SBF
The suction blister technique is a validated noninvasive method to collect interstitial fluid (27, 28) , and we have previously used the technique (18) . Briefly, blisters are formed by applying vacuum to the abdominal skin surface using small plastic containers with 28 circular openings (7 3 4), each with a diameter of 5 mm. After 60 to 90 minutes of vacuum, 28 individual suction blisters are formed in the lamina lucida of the epidermal basement membrane. The blisters can be harvested for up to 1.5 mL of SBF with a sterile syringe. SBF contaminated with blood was not collected. SBF was stored at 280°C.
Assays
All samples were analyzed blinded to treatment. For each individual, samples from the two treatments (placebo and prednisolone) were analyzed within the same assay run.
IGF immunoassays
Concentrations of IGF-I (total IGF-I) and IGFBP-3 were measured by the iSYS/IDS platform (Immunodiagnostic Systems Nordic A/S, Herlev, Denmark) (29, 30) . Serum total IGF-II concentrations were assayed by validated in-house, timeresolved immunofluorometric assay (31) . Intact IGFBP-4 and its N-terminal fragment specifically generated by PAPP-A (NT-IGFBP4) were determined by in-house time-resolved immunofluorometric assays based on monoclonal antibodies and recombinant calibrators from HyTest Ltd (Turku, Finland) (32) . PAPP-A and PAPP-A2 were determined by commercial enzyme-linked immunosorbent assays from Ansh Laboratories (Webster, TX) and STC2 by an in-house assay (24) .
IGF-IR bioassay
The ability of IGFs in serum or SBF to activate the IGF-IR in vitro was determined by kinase receptor activation (KIRA) assay, based on HEK293 cells transfected with complementary DNA encoding the human IGF-IR. The KIRA assay was conducted as originally described (33) with minor modifications as recently published (34) . As both IGF-I and IGF-II can activate the IGF-IR (33), the assay output has been designated "bioactive IGF."
IGFBP-3 degradation by Western immunoblotting
This was measured as recently described using a primary polyclonal antibody from R&D Systems (Abingdon, UK) (31) . The degradation of IGFBP-3 was calculated as the intensity of fragmented bands relative to the intensity of all bands representing IGFBP-3 immunoreactivity, with results expressed as a percentage.
Intracellular IGF-IR signaling
As glucocorticoid may affect post-IGF-IR signaling (13), cell lysates obtained after stimulation by serum and SBF were assayed for some of the key signaling proteins: IRS-1, protein kinase B (Akt), and mammalian target of rapamycin (mTOR) by Western blotting (antibodies are listed in the Supplemental Methods). The immunoblotting was performed in accordance with standard procedures, which are detailed in the Supplemental Methods. Mean intensities were calculated and used for semiquantitative analysis, expressed as the ratio between phosphorylated protein and the total protein measurement. Differences between interventions are expressed as the ratio change between measurements made following prednisolone and placebo at day 5.
Real-time quantitative polymerase chain reaction in skeletal muscle biopsy specimens from vastus lateralis Tissues were cleaned, rinsed, snap frozen in liquid nitrogen, and stored at 280°C until homogenization in Trizol, using a tissue homogenizer (Precellys 24; Bertin Instruments, Bretonneux, France). Total RNA was isolated according to standard procedures, as detailed in the Supplemental Methods.
Real-time quantitative polymerase chain reactions were performed with iTaq Universal SYBR Green Supermix on a CFX96 Touch system (Bio-Rad, Hercules, CA) as detailed in the Supplemental Methods. Primers for IGF-I, IGF-IR, and the three normalization genes b2-Microglobulin, GPX4, and YWHAQ were designed to be separated by an intron of at least 500 bp using the NCBI Primer-Blast tool, based on NCBI reference sequence IDs. Primers for STC1 and STC2 were predesigned from Sigma-Aldrich, Brøndby, Denmark. The sequences of forward and reverse primers are stated in the Supplemental Methods.
Inflammatory proteins
Interleukins (ILs) and tumor necrosis factor-a were measured by magnetic Bio-Plex Pro Assay (Bio-Rad), according to instructions. Data were analyzed by Bio-Plex Manager 6.0 software (Bio-Rad). Detection limits ranged between 0.5 and 5 ng/L.
Statistics
All statistical analyses and figures were made using Stata 13 (StataCorp, College Station, TX). The effects of treatment and time and their interactions on dependent variables were analyzed using a mixed-effect linear model with repeated measurements. Order of treatment (placebo-prednisolone or prednisolone-placebo) and period (session 1 or session 2) was accounted for in the model. Model validation was performed by comparing observed and expected within-subject standard deviations and correlations, as well as by inspecting QQ-plots of residuals under the model. The major objective was to test for interaction of treatment (placebo/prednisolone) and time. When variables showed interaction between treatment and time (P value given as P interaction ), post hoc analyses testing the effect of treatment at each time point were performed. When variables showed no interaction, the outcome was tested for the main effect of treatment (P value given as P treatment ). Paired difference estimates were compared by Friedman's test (followed by the Student-Newman-Keul test for multiple comparisons), Student paired t test, or Wilcoxon signed-rank test as appropriate. Paired comparisons of concentrations in serum and SBF are given as P compartment . Paired ratios of concentrations in SBF and serum following placebo and prednisolone are given as P ratio . Normal distribution was evaluated by inspection of QQ-plots.
Data are presented as mean and confidence interval or as median and interquartile range (25%-75%) as appropriate. P values ,0.05 were considered significant.
Results
Participants (n = 19)
During the study, cases of increased appetite (n = 3), restlessness (n = 2), sleep disturbance (n = 2), and increased vitality (n = 1) were observed. After the study, one participant displayed depressed mood (a few days), and one participant showed symptoms of infection (fever, cough). No serious adverse events were observed. Compliance to treatment was 100% (data not shown).
Circulating concentrations (n = 19)
Circulating IGF protein concentrations are shown in Table 2 and Fig. 1 . Serum total IGF-I and bioactive IGF increased steadily during prednisolone compared with placebo (P interaction # 0.001; Fig. 1A and 1B) . Total IGF-II and IGFBP-3 concentrations showed no differences in their development over time when comparing placebo and prednisolone, but overall, both peptides became suppressed during prednisolone (P # 0.001). Intact IGFBP-4 (P interaction = 0.01) and the PAPP-A-generated NT-IGFBP-4 fragment were mutually suppressed by prednisolone (P treatment = 0.02; Fig. 1C ), whereas both PAPP-A and PAPP-A2 ( Fig. 1D and 1E ) remained unaffected by prednisolone. However, in contrast to PAPP-A, which remained unchanged during the study, PAPP-A2 decreased to the same degree from day 1 to day 5 during placebo [data are mean (95% confidence interval)] [0.16 (0.14 to 0.18) vs 0.12 (0.10 to 0.15) mg/L; P , 0.001] and prednisolone [data are mean (95% confidence interval)] [0.15 (0.13 to 0.18) vs 0.12 (0.09 to 0.14) mg/L; P , 0.001]. STC2 was reduced during prednisolone (P treatment = 0.03; Fig. 1F ), and the same was true for IGFBP-2 (P = 0.04) and IGFBP-1 (P = 0.0014).
Comparison of compartments: serum vs SBF (n = 9)
In general, most analytes presented at lower concentrations in SBF than serum, irrespective of treatment (Table 3 ). This included IGF-I and IGFBP-1, IGFBP-2, and IGFBP-3 (P , 0.05), whereas IGF-II tended to be reduced (P = 0.07). These changes did not translate to bioactive IGF, as levels were similar in serum and SBF after placebo as well as after prednisolone.
Intact IGFBP-4 and STC2 were lower in SBF than plasma following placebo (P compartment , 0.01); after prednisolone, no compartment differences were observed. PAPP-A (P compartment , 0.01) and PAPP-A2 (P compartment , 0.03) were the only analytes being markedly higher in SBF than serum: irrespective of treatment, SBF concentrations of PAPP-A (P compartment = 0.008) and PAPP-A2 (P compartment = 0.03; n = 6) were 7-fold and .30-fold elevated, respectively, compared with serum.
As levels of IGF proteins in SBF are likely to reflect their circulating concentrations, we calculated SBF levels relative to serum or plasma (Fig. 2) . Bioactive IGF was relatively lower (~28%) in SBF following prednisolone compared with placebo (median SBF/serum concentrations): 2.5 mg/L/2.6 mg/L (prednisolone) vs 2.4 mg/L/ 1.8 mg/L (placebo); P ratio = 0.02 (Fig. 2C) . Thus, even though prednisolone increased serum bioactive IGF above placebo levels, this did not translate into higher levels in SBF. Other differences included STC2, which was relatively increased in SBF following prednisolone (median SBF/serum concentrations): 27 mg/L/25 mg/L (prednisolone) vs 22 mg/L/28 mg/L (placebo); P ratio = 0.02 (Fig. 2D) . Prednisolone did not affect relative SBF levels of PAPP-A, Data are presented as mean (95% confidence interval), n = 19. NT-IGFBP-4 is the specific N-terminal fragment generated by a PAPP-A-mediated proteolysis of IGFBP-4. NT-IGFBP-4 is measured by a fragment-specific assay (32) (n = 19). All statistically significant P values are stated in bold.
Abbreviations: ANOVA, analysis of variance; RM, repeated measures. a Main effect of treatment, P treatment .
Remaining P values are P interaction and reflect the interaction between treatment and time.
whereas the SBF to serum ratio of PAPP-A2 was slightly but significantly higher after prednisolone than placebo (32-fold vs 31-fold; P ratio = 0.03). The SBF to serum ratio of intact IGFBP-4 remained unaffected by prednisolone. However, when comparing the ratio of NT-IGFBP-4 to intact IGFBP-4 in SBF, a lower value was obtained after prednisolone than placebo (median concentrations): 69 mg/L/110 mg/L (prednisolone) vs 83 mg/L/121 mg/L (placebo); P = 0.04 (Fig. 2E ). This suggests that the PAPP-A-mediated cleavage of IGFBP-4 in SBF was reduced by prednisolone.
IGFBP-3 fragmentation
Overall, the majority of IGFBP-3 presented as fulllength IGFBP-3 in serum, whereas the opposite was observed in SBF ( Fig. 2) (all P values ,0.05). During the study, IGFBP-3 degradation remained unchanged, and prednisolone did not have any effect in either serum or SBF.
Effect of prednisolone treatment on signaling downstream of the IGF-IR
Crude cell lysates from the IGF-IR-transfected cells were used to compare post-IGF-IR signaling in cells exposed to serum obtained after prednisolone and placebo, respectively (n = 19). When comparing absolute densities, prednisolone did not alter the density of the phosphorylated proteins IRS-1, Akt, and mTOR (data not shown). However, when the phosphorylated protein densities were normalized to the concentration of activated IGF-IRs as measured by the KIRA assay, serum obtained after prednisolone reduced phosphorylation of IRS-1 (~15%; Fig. 3A ; P = 0.01), Akt (~30%; Fig. 3B ; P = 0.000), and mTOR (~30%; Fig. 3C ; P = 0.001) compared with serum obtained after placebo. A similar pattern was observed for SBF (n = 9), although some of these changes did not reach statistical significance.
Real-time quantitative polymerase chain reaction in skeletal muscle biopy specimens from the vastus lateralis muscle
To assess effects of glucocorticoid within the tissues, the skeletal muscle expression of IGF-I, IGF-IR, STC2, and the related STC1 (22, 24) was determined. However, no changes were observed (data not shown).
Cytokines
Irrespective of treatment, levels of IL-1b, IL-2, IL-6, IL-10, and tumor necrosis factor-a were elevated to the same degree in SBF as serum (Supplemental Table 1 ; all P , 0.05). In contrast, levels of IL-4, IL-5, IL-12, IL-13, and interferon-g were lower in SBF than serum (P , 0.05), again without differences between the treatments.
Discussion
This study aimed to identify the mechanisms by which glucocorticoid inhibits IGF-I actions in humans with specific emphasis on the ability of serum and interstitial fluid to promote IGF-IR activation and downstream signaling. To this end, we performed a randomized, placebo-controlled crossover study comparing 5 days of treatment with prednisolone (37.5 mg/d) vs placebo in healthy males. The major findings summarize as follows: short-term prednisolone treatment (1) increased serum IGF-I concentration and bioactive IGF, (2) did not change IGF-I concentration and bioactive IGF in interstitial fluid, (3) induced IGF-I resistance by impeding post-IGF-IR signaling in IGF-IR-transfected cells, and (4) did not change skeletal muscle messenger RNA levels of IGF-I, IGF-IR, or the two stanniocalcins. Thus, short-term prednisolone administration appears to exert distinct, compartment-specific effects on IGF-I action. Finally, we demonstrated that levels of PAPP-A and PAPP-A2 are markedly higher in lymph-like fluid than serum.
Prednisolone treatment increased serum IGF-I concentrations and caused minor reductions in IGFBP-1 to IGFBP-4 and IGF-II. These findings concur with earlier observations (6, 7, 9, 11, 12) . It is plausible that the increases in IGF-I concentration and bioactive IGF represent the aftermath of prednisolone-induced insulin resistance. Supportive of this, prednisolone suppressed IGFBP-1 and IGFBP-2, which in an inverse manner reflect the hepatic exposure to insulin (35) . An increased hepatic insulin exposure augments the hepatic growth hormone receptor expression and hence the ability of growth hormone to generate IGF-I (36).
Prednisolone increased serum bioactive IGF but instigated at the same time cellular IGF-I resistance by disabling IGF-IR downstream signaling. Thus, cells exposed to serum obtained after 5 days of prednisolone 
Comparison of paired estimates; P compartment compares SBF and serum. P ratio compares the ratios between analyte levels in SBF and serum/plasma following prednisolone treatment vs placebo treatment. PAPP-A2 was only determined on days 1 and 5.
Abbreviation: IQR, interquartile range.
contained less of the phosphorylated forms of IRS-1, Akt, and mTOR than after exposure to serum obtained after placebo. The inhibition of IRS-1 suggests that prednisolone targets the proximal level of the IGF-IR signaling cascade. As serum was only incubated with IGF-IRtransfected cells for 15 minutes, the inhibition of IGF-IR signaling most likely illustrates a nongenomic effect of prednisolone. This observation is in agreement with earlier experimental findings. As reviewed by Schakman et al. (13) , glucocorticoids can inhibit post-IGF-IR signaling through nongenomic mechanisms, including suppression of the cellular IRS-1 expression and synthesis as well as through inactivation of IRS-1 by phosphorylation of its serine residues (13).
Early observations, based on end-point bioassays that measured incorporation of radiolabeled sulfate or thymidine into cultures of porcine cartilage, proposed the existence of a circulating IGF-I inhibitor, being induced by systemic glucocorticoid treatment (5, 6) . Even though the nature of this inhibitor has remained unidentified, we have data to support its existence. In prepubertal children, a modest dose of systemic prednisolone (5 mg/d for 7 days) reduced bioactive IGF by 13%, even though serum concentrations of free IGF-I, total IGF-I, and IGFBP-1 to IGFBP-3 remained unaffected (10) . In contrast, the current study demonstrated increased serum levels of bioactive IGF (i.e., increased ability to activate the IGF-IR in vitro) following systemic prednisolone, whereby it apparently refutes the existence of the circulating IGF-I inhibitor. Importantly, however, our two studies are far from comparable. First, the present dose of prednisolone was approximately threefold higher than that used in our previous study (~0.45 vs~0.15 mg per kg body weight) (10) . Second, the two studies showed very distinct responses of the circulating IGF system to prednisolone. In the present (high-dose) study, prednisolone concomitantly increased serum IGF-I concentrations and reduced those of IGFBP-1 and IGFBP-2, changes that explain the increase in bioactive (i.e., free) IGF-I. In contrast, in our first (low-dose) study, prednisolone changed neither IGF-I nor IGFBP concentrations. Importantly, however, our present data do not exclude the existence of a glucocorticoidinduced circulating IGF-I inhibitor targeting the intracellular IGF-IR signaling cascade, as this in theory could explain why an increased IGF-IR phosphorylation was not accompanied by an increased activation of key signaling proteins downstream of the IGF-IR.
Of notice, the potential of prednisolone to increase serum IGF-I concentration and bioactive IGF did not translate to SBF. Indeed, when expressed relative to serum, the ability of SBF to activate the IGF-IR in vitro was significantly lower in SBF after prednisolone treatment. As SBF concentrations of IGF-I, IGF-II, IGFBP-1 to IGFBP-3, intact IGFBP-4, and PAPP-A remained virtually unaffected by prednisolone treatment, these proteins are unlikely to explain the relative reduction in IGF bioactivity in SBF following prednisolone treatment.
However, despite identical SBF levels of intact IGFBP-4, the SBF concentration of the NT-IGFBP-4 fragment, which reflects the ability of PAPP-A to cleave IGFBP-4 (32), was reduced following prednisolone compared with placebo. This observation, pointing toward a compromised PAPP-A activity following prednisolone treatment, drew our attention to STC2, which by covalent binding to PAPP-A irreversibly inhibits its enzymatic activity (24) . In fact, measurement of SCT2 demonstrated that the concentration of the PAPP-A inhibitor was relatively increased in SBF following prednisolone. Taken together, our data indicate that prednisolone may compromise the ability of PAPP-A to release IGFBP-4-complexed IGF in the tissues via local STC2. However, to prove this hypothesis, novel experiments measuring the actual complex formation between PAPP-A and STC2 as well as the specific PAPP-A enzymatic activity are required.
The hypothesis that prednisolone may inhibit IGF-I action via STC2 gains support from experimental studies demonstrating that STC2 is a negative regulator of growth. Mice deficient of STC2 are 10% to 15% larger (37), whereas mice overexpressing STC2 are 40% smaller than their respective littermates (38) . Interestingly, genetic manipulation of STC2 does not affect growth hormone and IGF-I expression or serum IGF-I concentrations (37, 38) . Rather, STC2 inhibits the enzymatic activity of PAPP-A by covalent binding to the enzyme, whereby its ability to liberate tissue IGF becomes compromised (22, 24) .
STC2 is expressed in multiple tissues, but the factors that regulate STC2 expression remain unsettled. Therefore, we determined STC2 gene expression in skeletal muscle. However, prednisolone appeared to induce no changes in STC2 expression. Thus, we hypothesize that the relative increase in STC2 levels observed in SBF following prednisolone treatment is caused by an increased efflux from the circulation and/or a reduced interstitial clearance. However, this remains to be studied in further detail.
PAPP-A is stimulated by proinflammatory cytokines such as tumor necrosis factor-a, IL-1b, and IL-6 (26), which may change during prednisolone administration (39, 40) . However, in this cohort of healthy males, prednisolone treatment had no impact on levels of proinflammatory proteins, nor did it alter the concentrations of PAPP-A and PAPP-A2. Nevertheless, we find it noteworthy that both proteases were present in much higher concentrations in SBF than serum. This observation supports the view that these IGF-liberating enzymes are predominantly expressed and operative within tissues and extravascular fluids (17, 22) .
Our study contains limitations. We show that prednisolone inhibits IGF-IR signaling in vitro without altering the skeletal muscle expression of IGF-I or IGF-IR. Thus, our study only suggests that similar mechanisms may occur in vivo. Furthermore, due to the apparent dose effect of prednisolone, the present data cannot be extrapolated to other prednisolone doses or treatment periods without caution. Finally, although we studied numerous members of the IGF system, we cannot preclude that glucocorticoids may affect some of the IGFBPs not determined in the current study (i.e., IGFBP-5 and IGFBP-6) and other IGFBP proteases (21) than PAPP-A and PAPP-A2.
In conclusion, 5 days of prednisolone treatment (37.5 mg/d) appears to alter the IGF system in a compartment-specific manner. In serum, prednisolone augmented IGF-I concentrations and bioactive IGF, most likely secondary to increased insulin resistance. In cell cultures, prednisolone appeared to suppress the post-IGF-IR signaling cascade, presumably via nongenomic mechanisms. In SBF, which served as a proxy of interstitial fluid, IGF and IGFBP concentrations were unaffected by prednisolone, whereas bioactive IGF was relatively reduced. In this compartment, we found evidence of a reduced enzymatic activity of PAPP-A, most likely mediated via STC2. However, this requires further confirmation. Taken together, our study supports the hypothesis that glucocorticoids primarily impair the anabolic actions of IGF-I within the tissues rather than by suppressing endocrine IGF-I action.
